How Does Lynparza Work? Mechanism of Action Explained in Plain English

To understand how Lynparza works, you need to understand a bit about how cancer cells and healthy cells handle DNA damage—and why cancer cells with BRCA mutations are uniquely vulnerable to Lynparza. This is actually a fascinating story of molecular biology that led to one of oncology's most important breakthroughs.

First: Why Does DNA Damage Matter?

Every cell in your body has DNA—the instruction manual for how the cell works. DNA gets damaged thousands of times every day from normal cellular processes, radiation, environmental exposures, and more. Fortunately, cells have multiple backup systems—called DNA repair pathways—to fix this damage. Think of these as a team of repair crews.

When these repair systems fail, cells can either die naturally or mutate and grow out of control—which is how cancer starts.

What Does BRCA Have to Do with It?

BRCA1 and BRCA2 are tumor suppressor genes that normally help manage a major DNA repair system called homologous recombination repair (HRR). HRR is your cell's most accurate method for fixing serious DNA breaks—especially double-strand breaks (when both strands of the DNA helix are cut).

When someone has a BRCA1 or BRCA2 mutation, this primary repair pathway is broken. Cancer cells with BRCA mutations become dependent on a backup repair system to survive—and that backup system relies heavily on an enzyme called PARP.

What Is PARP?

PARP stands for poly (ADP-ribose) polymerase. It's a family of enzymes (Lynparza targets PARP1, PARP2, and PARP3) that help detect and repair single-strand DNA breaks—smaller, more common types of DNA damage. Think of PARP as a crew that fixes minor road cracks. In normal cells, both the PARP pathway and the BRCA/HRR pathway work together to keep DNA intact.

The Core Concept: Synthetic Lethality

Here's where Lynparza's genius comes in. Lynparza blocks PARP—it prevents PARP from fixing those minor DNA cracks. For normal healthy cells (which still have working BRCA and HRR), this is manageable. The cell can use its HRR backup system to compensate for the loss of PARP repair.

But for cancer cells with BRCA mutations? The HRR pathway is already broken. When Lynparza blocks PARP too, these cancer cells suddenly have no working DNA repair system at all. DNA damage accumulates rapidly. The cancer cell can't survive and dies.

This concept—where two defects together are lethal when either one alone would not be—is called synthetic lethality. It's the scientific principle that makes Lynparza selectively kill BRCA-mutated cancer cells while largely sparing normal cells.

Beyond PARP Inhibition: PARP Trapping

Lynparza doesn't just block PARP—it also physically "traps" PARP proteins onto DNA strands. This trapping prevents other repair proteins from accessing the damaged site, making the DNA damage even more permanent. This PARP-trapping mechanism is thought to contribute significantly to Lynparza's cancer cell-killing effectiveness.

Why Does Lynparza Work in More Than Just BRCA-Mutated Cancers?

BRCA1 and BRCA2 aren't the only genes involved in homologous recombination repair. There are actually many other genes in the HRR pathway—including ATM, PALB2, CHEK2, and others—and mutations in any of them can create a similar vulnerability to PARP inhibitors. This is why Lynparza is also approved for prostate cancers with broader HRR gene mutations.

How Does Lynparza Move Through the Body?

After you take Lynparza by mouth, it is absorbed through the digestive tract and enters the bloodstream. It is metabolized primarily by the CYP3A enzyme system in the liver, which is why drugs that affect CYP3A (inhibitors or inducers) can significantly change olaparib blood levels. Lynparza has a half-life of approximately 14.9 hours, which is why twice-daily dosing (approximately 12 hours apart) is used to maintain steady therapeutic levels.

Why Was Lynparza Such a Big Deal When It Was Approved?

When Lynparza was approved by the FDA in 2014, it was the first PARP inhibitor ever approved for any cancer. The concept of synthetic lethality had been theorized for decades, but Lynparza was the first proof that it could be turned into an effective medicine. Since its approval, Lynparza has been prescribed to approximately 45,500 patients over 10 years, and it has spawned an entire new class of cancer drugs.

Want to know more about what Lynparza is approved to treat and how to take it? See: What Is Lynparza? Uses, Dosage, and What You Need to Know in 2026.

Getting Your Lynparza Prescription

Lynparza is a specialty medication filled through specialty pharmacies. If you're having trouble locating a pharmacy that has it, medfinder can call pharmacies near you to find which ones have it in stock and can fill your prescription.